ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,070.55
      1.20%
      US Tech 100
      17,095.60
      2.05%
      Dow Jones
      38,503.69
      0.69%
      Brent Oil
      87.675
      0.13%
      Bitcoin
      66,708.40
      0.45%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. AMEX
      6. Can Fite BioPharma Ltd (CANF)

      7. Can Fite BioPharma Ltd (CANF) News

      CANF

      Can Fite BioPharma (CANF)

      Can Fite BioPharma Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:AMEX:CANF
      DateTimeSourceHeadlineSymbolCompany
      04/15/20247:00AMBusiness WireCan-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASHAMEX:CANFCan Fite BioPharma Ltd
      04/03/20247:00AMBusiness WireCan-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH PatientsAMEX:CANFCan Fite BioPharma Ltd
      03/28/20247:00AMBusiness WireCan-Fite Reports 2023 Financial Results and Clinical UpdateAMEX:CANFCan Fite BioPharma Ltd
      03/11/20247:27AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      03/11/20247:00AMBusiness WireNamodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe ConferenceAMEX:CANFCan Fite BioPharma Ltd
      02/28/20247:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      02/28/20247:00AMBusiness WireCan-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in CanadaAMEX:CANFCan Fite BioPharma Ltd
      02/14/20243:32PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsAMEX:CANFCan Fite BioPharma Ltd
      01/30/20247:24AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      01/30/20247:00AMBusiness WireCan-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer IndicationAMEX:CANFCan Fite BioPharma Ltd
      01/29/20247:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      01/29/20247:00AMBusiness WireCan-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis StudyAMEX:CANFCan Fite BioPharma Ltd
      01/08/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CANFCan Fite BioPharma Ltd
      12/28/20234:16PMEdgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]AMEX:CANFCan Fite BioPharma Ltd
      12/20/20237:09AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      12/20/20237:00AMBusiness WireThe Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human StudiesAMEX:CANFCan Fite BioPharma Ltd
      12/18/20237:07AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      12/18/20237:00AMBusiness WireCan-Fite Received FDA Positive Response to Psoriasis Pediatric PlanAMEX:CANFCan Fite BioPharma Ltd
      12/12/20234:15PMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersAMEX:CANFCan Fite BioPharma Ltd
      12/04/20237:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      12/04/20237:00AMBusiness WireCan-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical DevelopmentAMEX:CANFCan Fite BioPharma Ltd
      11/30/20237:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      11/30/20237:00AMBusiness WireCan-Fite Reports Third Quarter 2023 Financial Results and Clinical UpdateAMEX:CANFCan Fite BioPharma Ltd
      11/22/20234:20PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]AMEX:CANFCan Fite BioPharma Ltd
      11/22/20234:15PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      11/21/20234:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      11/21/20231:53PMGlobeNewswire Inc.Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross ProceedsAMEX:CANFCan Fite BioPharma Ltd
      11/21/20237:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      11/21/20237:00AMBusiness WireCan-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with NamodenosonAMEX:CANFCan Fite BioPharma Ltd
      11/01/20237:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
       Showing the most relevant articles for your search:AMEX:CANF